Long-acting insulin analogs

Diabetes Care

Volumn 22, Issue SUPPL. 2, 1999, Pages

  Rosskamp, Ralf H ^a,b   Park, Glen ^a  

^a HMR Global Clin R and D   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; NOVOSOL BASAL; UNCLASSIFIED DRUG; WW 99 S32;

CARCINOGENIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG FORMULATION; DRUG SAFETY; HUMAN; INSULIN TREATMENT; ISOELECTRIC POINT;

ACYLATION; AMINO ACID SUBSTITUTION; CLINICAL TRIALS, PHASE II; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0032973103     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Banting FG, Campbell WR, Fletcher AA: Further clinical experience with insulin (pancreatic extracts) in the treatment of diabetes mellitus. Br Med J 8-12, 1923
2. Dȯrzbach E, Müller R: Die Insulintherapie: Die Insulinprȧparate. In Handbuch des Diabetes mellitus II. München, Germany. Lehmann's Verlag, 1971
3. Hagedorn HC, Jensen BN, Krarup NB, Wodstrug I: Protamine insulinate. J Am Med Assoc 106: 177-180, 1936
4. Lautenschlȧger KL, Dörzbach E, Schaumann O: Verfahren zur Herstellung von Präparaten aus dem blutzuckersenkenden Hormon der Bauchspeicheldrüse. D R Patent 727888, 1937
5. Hallas-Moller K: The lente insulins. Diabetes 5:7-14, 1956
6. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:978-986, 1993
7. Hildebrandt P, Berger A, Volund A, Kuhl C: The subcutaneous absorption of human and bovine ultralente insulin formulations. Diabet Med 2:355-359, 1985
8. Francis AJ, Hanning I, Alberti KGMM: Human ultralente insulin: a comparison with porcine lente insulin as a twice daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia. Diabetes Res Clin Pract 3:263-268, 1986
9. Ebeling P, Jansson P, Smith U, Lalli C, Bolli GB, Doivisto VA: Strategies toward improved control during insulin lispro therapy in IDDM. Diabetes Care 20:1287-1289, 1997
10. Heinemann L, Richter B: Clinical pharmacology of human insulin. Diabetes Care 16 (Suppl. 3):90-100, 1993
11. Lorenz RA, Santiago JV, Siebert C, Cleary PA, Heyse S: Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 90:450-459, 1991
12. Bendtson I: Nocturnal hypoglycaemia in patients with insulin-dependent diabetes mellitus. Dan Med Bull 42:269-284, 1995
13. Bolli GB, Perriello G, Fanelli CG, DeFeo P: Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care 16 (Suppl. 3):71-89, 1993
14. Binder C: Absorption of injected insulin. Acta Pharmacol Toxicol 27 (Suppl. 2):1-84, 1969
15. Lauritzen T, Pramming S, Deckert T, Binder C: Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 24:326-329, 1983
16. Lauritzen T, Faber OK, Binder C: Variation in insulin absorption and blood glucose concentration. Diabetologia 17:291-295, 1979
17. Lauritzen T, Pramming S, Gale EAM, Deckert T, Binder C: Absorption of isophane (NPH) insulin and its clinical implications. BMJ 285:159-62, 1982
18. Binder C, Lauritzen T, Faber O, Pramming S: Insulin pharmacokinetics (Review). Diabetes Care 7:188-199, 1984
19. Binder C: A theoretical model for the absorption of soluble insulin. In Artificial Systems for Insulin Delivery. Brunetti P, Alberti KGMM, Albisser AM, Hepp KD, Massi-Benedetti M, Eds. New York, Raven, 1983, p. 53-57
20. Anderson JH, Massey EH: Flocculated humulin N insulin (Letter). N Engl J Med 316:1027, 1987
21. Dubrey S, Huehns TY, Simpson R: Defrosting insulin: a case report. Postgrad Med J 70:653-654, 1994
22. Weiss ME, Nyhan D, Peng Z, Horrow JC, Lowenstein E, Hirshman C, Adkinson NF Jr: Association of proteine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 320:886-891, 1989
23. Jorgensen S, Vaag A, Langkjaer L, Hougaard P, Markussen J: NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analog. BMJ 299:415-459, 1989
24. Jorgensen S, Drejer K: Insulin analogs and nasal insulin delivery. In New Antidiabetic Drugs. 1st ed. Bailey CJ, Flatt PR, Eds. London, Smith-Gordon, 1990, p. 83-92
25. 2, a new retardation principle based on a natural proinsulin-derived processing intermediate (Abstract). Diabetes Res Clin Pract 1:204, 1985
26. Hilgenfeld R, Dörschug M, Geisen K. Neubauer H, Obermeier R, Seipke G, Berchtold H: Controlling insulin bioavailability by crystal contact engineering (Abstract). Diabetologia 35 (Suppl. 1):A193, 1992
27. Dreyer M, Pein M, Schmidt Chr, Heidtmann B, Schlunzen M, Rosskamp D: Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31, B32)-human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique (Abstract). Diabetologia 37 (Suppl. 1):A78, 1994
28. Coates PA, Mukherjee S, Luzio S, Srodzinski KA, Kurzhals R, Rosskamp R, Owens DR: Pharmacokinetics of a 'long-acting' human insulin analog (HOE 901) in healthy subjects (Abstract). Diabetes 44 (Suppl. 1):130A, 1995
29. Talaulicar M, Willms B, Rosskamp R: HOE 901, ein neues Insulinanalogon zur Substitution des basalen Insulin-bedarfs bei Type I Diabetes. Diabetes und Stoffwechsel 5:3-6, 1996
30. Rosenstock J, Park G, Zimmerman J: Efficacy and safety of HOE 901 in patients with type 1 DM: A four-week randomized, NPH insulin-controlled trial (Abstract). Diabetes 47 (Suppl. 1):A92, 1998
31. Pieber T, Eugene-Jolchine I, DeRobert E: Efficacy and safety of HOE 901 in patients with type 1 diabetes: A four-week randomised. NPH insulin-controlled trial (Abstract). Diabetes 47 (Suppl. 1):A62, 1998
32. Raskin P, Park G, Zimmerman J: The effect of HOE 901 on glycemic control in type 2 diabetes (Abstract). Diabetes 47 (Suppl. 1):A103, 1998
33. Matthews DR, Pfeiffer C: A new long-acting insulin (HOE 901) demonstrates less nocturnal hypoglycaemia when compared with protamine insulin in a clinical trial (Abstract). Diabetologia 41 (Suppl. 1):A245, 1998
34. Drejer K: The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259-286, 1992
35. b32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259-265, 1997
36. Barnett AH, Owens DR: Insulin analogues. Lancet 349:47-51, 1997
37. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, Larsen UD, Ribel U, Schaffer L, Vad K, Jonassen K: Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39:281-288, 1996
38. Schaffer L, Jonassen IB, Markussen J. Havelund S, Kurtzhals P, Ribel U, Larsen UD, Hasselager E, Loftager M: NN-304: A new, soluble, long-acting insulin analog (Abstract), Diabetes 45 (Suppl. 2):139A, 1996
39. Howey DC, Woodworth JR, Bowsher RR, Reviergo J: Pharmacokinetic and glucodynamic assessments of palmitoyl, LYS (B29) human insulin in healthy volunteers (Abstract). Diabetologia (Suppl. 1):A354, 1997